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Background: In approximately 10% of newly diagnosed individuals in Europe, HIV-1 variants harboring transmitted
drug resistance mutations (TDRM) are detected. For some TDRM it has been shown that they revert to wild type
while other mutations persist in the absence of therapy. To understand the mechanisms explaining persistence we
investigated the in vivo evolution of frequently transmitted HIV-1 variants and their impact on in vitro replicative
capacity.
Results: We selected 31 individuals infected with HIV-1 harboring frequently observed TDRM such as M41L or
K103N in reverse transcriptase (RT) or M46L in protease. In all these samples, polymorphisms at non-TDRM positions
were present at baseline (median protease: 5, RT: 6). Extensive analysis of viral evolution of protease and RT demonstrated
that the majority of TDRM (51/55) persisted for at least a year and even up to eight years in the plasma. During follow-up
only limited selection of additional polymorphisms was observed (median: 1).
To investigate the impact of frequently observed TDRM on the replication capacity, mutant viruses were constructed
with the most frequently encountered TDRM as site-directed mutants in the genetic background of the lab strain
HXB2. In addition, viruses containing patient-derived protease or RT harboring similar TDRM were made. The replicative
capacity of all viral variants was determined by infecting peripheral blood mononuclear cells and subsequently
monitoring virus replication. The majority of site-directed mutations (M46I/M46L in protease and M41L, M41L + T215Y
and K103N in RT) decreased viral replicative capacity; only protease mutation L90M did not hamper viral replication.
Interestingly, most patient-derived viruses had a higher in vitro replicative capacity than the corresponding site-directed
mutant viruses.
Conclusions: We demonstrate limited in vivo evolution of protease and RT harbouring frequently observed TDRM in
the plasma. This is in line with the high in vitro replication capacity of patient-derived viruses harbouring TDRM
compared to site-directed mutant viruses harbouring TDRM. As site-directed mutant viruses have a lower replication
capacity than the patient-derived viruses with similar mutational patterns, we propose that (baseline) polymorphisms
function as compensatory mutations improving viral replication capacity.
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The viral enzymes reverse transcriptase (RT) and prote-
ase were the first targets of antiretroviral therapy and
the most commonly used drug regimens still aim at inhi-
biting these viral proteins [1]. In resource-rich settings,
drug resistance mutations in protease and RT are detected
in 10-15% of newly diagnosed HIV patients [2,3].
The majority of transmitted drug-resistant viruses
contain limited resistance profiles to single drug clas-
ses. Nucleoside RT inhibitor (NRTI) mutations are the
most frequently observed transmitted drug resistance
mutations (TDRM). Especially thymidine analogue muta-
tions (TAMs) M41L and T215 variants, that have been
selected by drugs extensively used in the past, are often
observed in newly diagnosed patients [4]. A worrying
trend is the increased prevalence of non-nucleoside RT
inhibitor (NNRTI) related mutations in newly diagnosed
patients [3,5], as single NNRTI mutations, such as the fre-
quently observed K103N mutation, can result in high
levels of resistance against first generation NNRTIs [6]. In
protease, M46I/L and L90M are the most frequently ob-
served TDRM [2,3]. When present in combination with
other protease drug resistance mutations, both M46I/L
and L90M are related to reduced susceptibility to several
protease inhibitors (PIs) [6].
It is generally acknowledged that most drug resistance
mutations decrease the replicative capacity (RC) of HIV-
1 [7,8]. As such, in the absence of drugs TDRM can re-
vert to wild type, thereby increasing viral RC. Indeed,
follow-up of untreated individuals diagnosed with a drug
resistant HIV variant revealed that certain mutations with
a detrimental effect on the viral RC, such as M184V in
RT, after transmission to a new host often revert rapidly
in the plasma [9,10]. In addition, the use of very sensi-
tive assays shows that minority drug resistance mutations
are frequently found in untreated individuals, suggestive
of reversion after transmission [11,12].
However, follow-up of patients diagnosed with HIV-1
harboring TDRM has revealed that TAMs, PI- and
NNRTI-related TDRM often persist for prolonged pe-
riods [10,13-25]. The mechanisms explaining persistence
have not been fully resolved. Based on the available litera-
ture [13,15-25], we have previously proposed two possible
mechanisms to explain persistence of TDRM [9]. When
the effect of the TDRM on the RC is very small, reversion
may take a very long time. Alternatively, when the TDRM
decreases the RC considerably the presence or selection of
additional compensatory mutations can prevent reversion
of the TDRM.
The aim of our study was to gain more insight in the
mechanisms causing persistence of drug resistant HIV-1
variants after transmission. Therefore, we investigated
the molecular evolution of HIV-1 protease and RT har-
boring the most frequently observed TDRM in greatdetail. The majority of TDRM persisted during the follow-
up, and only few additional polymorphisms were selected
during this period. Most patient-derived viruses had a
higher RC than the corresponding site-directed mutant
viruses, indicating that persistence can be explained by
a high replication capacity of most transmitted drug re-
sistant HIV-1 variants.
Results
Patients diagnosed with a transmitted drug resistant
HIV-1 variant
To investigate the in vivo evolution of transmitted drug
resistant HIV variants, we selected 31 patients from four
European countries (Belgium, Greece, the Netherlands,
Slovenia) who were diagnosed in 2001 to 2008 with an
HIV variant harboring a frequently observed TDRM
(prevalence >5% in patients diagnosed with HIV-1 har-
boring TDRM in the SPREAD-programme). Patients
were included if a plasma sample was available at one
year (10–14 months) after diagnosis if therapy was not
yet initiated. If available, a third time point before start
of treatment was investigated. Prior negative HIV tests
were available for 14 patients, revealing that at least
nine patients had been infected for less than two years.
The majority of the patients were men having sex with
men (MSM), which is the most important route of
transmission in Western Europe. The median plasma
HIV-RNA in our group of patients was 4.6 log copies/
ml, comparable to the median HIV-RNA observed in
the SPREAD-programme in 2002–2006 (4.8 log cop-
ies/ml). The median baseline CD4 count was 653 cells/
mm3, which is higher than the median observed in the
SPREAD programme (343 cells/mm3) [3].
Surveillance studies demonstrated that most transmitted
drug resistant HIV-1 variants harbor resistance against a
single drug class [3,4]. In line with this observation, only
3/31 of the patients selected for this study had been diag-
nosed with an HIV-1 variant resistant to multiple drug
classes. A total of 55 mutations at positions included in
the WHO list for surveillance of transmitted drug resist-
ant HIV-1 [26] were observed in the transmitted viruses at
baseline. A single TDRM was detected in 10/16 patients
with viruses harboring only NRTI-related TDRM, for the
other six patients a profile of two to four TDRM was ob-
served. The vast majority of NRTI-related TDRM were
TAM-related mutations. In six of the selected patients
viral variants containing a single NNRTI-related TDRM
were observed. Six patients were diagnosed with HIV-1
harboring a single PI-related TDRM (Table 1). In addition
to TDRM, polymorphisms were present in all baseline se-
quences. For variants containing RT TDRM, the median
number of RT polymorphisms was 7 (range: 4–21) when
compared to HXB2 and 6 to consensus B (range: 2–19).
Viruses harboring PR resistance mutations had a median
Table 1 Patient characteristics, resistance mutations and evolution
ID Gender Last
negative
HIV test
Country
of origin
Diagnosis Risk
group
Months
after first
analysis
Plasma
HIV RNA
(copies/ml)
CD4
count
Sub-
type
Resistance
Profile PR
Resistance
Profile RT
p-distance p-value
dN/dS
Transmitted variants harboring only NRTI-related mutations
P01 Male NL May 2007 MSM 0 >750000 461 B M41L
10 M41L 0.001 1.000
16 M41L 0.002 0.290
P02 Male NL Jan 2008 MSM 0 21800 423 B M41L
12 M41L 0.005 0.225
28 M41L 0.005 0.225
P03 Male Jan 2004 BE Jun 2005 MSM 0 41000 483 B M41L
11 M41L 0.000 1.000
32 M41L 0.002 0.152
P04 Male NL Feb 2007 MSM 0 102000 322 B L210LS
11 - 0.000 1.000
25 - 0.002 1.000
P05 Male SL Jun 2001 MSM 0 12267 950 B T215D
12 T215D 0.011 0.060
99 T215D 0.007 0.428
P06 Male Mar 2005 SL Feb 2006 MSM 0 797000 953 B T215S
14 T215S 0.000 1.000
21 T215S 0.000 1.000
P07 Male NL Sep 2008 MSM 0 36300 521 B T215D
11 T215D 0.000 1.000
27 T215D 0.000 1.000
P08 Male Sep 2004 NL Dec 2004 MSM 0 583000 596 B T215IT
13 - 0.000 1.000
P09 Male Sep 2006 NL Sep 2007 MSM 0 158000 678 B T215AT
13 T215AT 0.001 0.294
20 T215A 0.000 1.000
P10 Male Oct 2003 NL Jan 2005 MSM 0 89800 289 B K219N
11 K219N 0.000 1.000
44 K219N 0.000 1.000
P11 Male BE Mar 2006 HSX 0 318000 966 B D67N T215C
13 D67N T215C 0.001 0.291
P12 Male NL Feb 2007 MSM 0 55900 609 B D67G T215C
K219E
11 D67G T215C
K219E
0.007 0.156
24 D67G T215C
K219E
0.000 1.000
P13 Male Jul 2004 NL Nov 2007 MSM 0 294000 531 B D67G T215C
K219E
12 D67G T215C
K219E
0.000 1.000
14 D67G T215C
K219E
0.000 1.000
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Table 1 Patient characteristics, resistance mutations and evolution (Continued)
P14 Male Apr 2005 NL Jun 2005 HSX 0 750000 577 B D67G T215C
K219E
14 D67G T215C
K219E
0.000 1.000
P15 Male NL Aug 2005 MSM 0 81000 470 B M41L T69S
T210E T215ST
1.000
11 M41L T69S
T210DE T215ST
0.000 1.000
39 M41L T69S
T210E T215ST
0.000 1.000
77 M41L T69S
T210E T215ST
0.000 1.000
P16 Male Mar 2005 NL Jun 2006 MSM 0 34600 1129 B M41L T69S
T210E T215ST
13 M41L T69AS
T210E T215ST
0.000 1.000
33 M41L T69S
T210E T215ST
0.001 1.000
49 M41L T69S
T210E T215ST
0.001 1.000
Transmitted variants harboring only NNRTI-related mutations
P17 Male Feb 2005 NL Sep 2006 MSM 0 5990 790 B K103N
12 K103N 0.000 1.000
30 K103N 0.000 1.000
P18 Male Jun 2004 BE Apr 2006 MSM 0 39900 648 B K103N
12 K103N 0.000 1.000
28 K103N 0.000 1.000
P19 Male NL Sep 2005 MSM 0 21400 359 B K103Q
12 K103Q 0.000 1.000
59 K103Q 0.001 0.304
P20 Male 1995 SL Sep 2005 MSM 0 29300 421 B Y181C
11 Y181C 0.000 1.000
49 Y181C 0.002 0.305
P21 Female GR Sep 2004 HSX 0 905 699 B G190A
10 B G190A 0.005 0.866
P22 Male GR Jun 2004 ? 0 10500 918 B G190A
13 B G190A 0.005 0.387
Transmitted variants harboring only PI-related mutations
P23 Male NL Apr 2007 HSX 0 700000 664 B M46L
14 M46L 0.000 1.000
22 M46L 0.000 1.000
P24 Male Jan 2006 NL Apr 2008 MSM 0 5170 742 B M46L
10 M46L 0.001 0.310
29 M46L 0.004 0.471
P25 Male Jul 2005 NL Aug 2008 MSM 0 421000 409 B M46L
14 M46L 0.000 1.000
23 M46L 0.000 1.000
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Table 1 Patient characteristics, resistance mutations and evolution (Continued)
P26 male NL Aug 2008 MSM 0 111000 657 B M46L
14 M46L 0.000 1.000
26 M46L 0.001 0.299
P27 male 05-11-04 NL Apr 2007 MSM 0 18100 699 B M46L
13 M46L 0.000 1.000
38 M46L 0.001 0.306
P28 male 15-02-03 NL Mar 2005 MSM 0 69000 480 B L90M
13 L90M 0.000 1.000
Transmitted variants harboring mutations against two drug classes
P29 male NL Dec 2001 MSM 0 288 1468 B D67G Y181CY
T215C K219E
10 D67G T215C
K219E
0.006 0.148
46 D67G T215C
K219E
0.000 1.000
P30 male NL Jan 2005 HSX 0 26600 667 B G73S L90M K103N
12 L90M K103N 0.001 0.306
18 L90M K103N 0.001 0.306
P31 female GR Jul 2004 HSX 0 696 1288 B I54V V82A
L90M
M41L D67N
L210W T215D
10 F53FL I54V
V82A L90M
M41L D67N
L210W T215D
0.001 0.293
Abbreviations: PR protease, RT reverse transcriptase, NRTI nucleoside reverse transcriptase inhibitor, NNRTI non- nucleoside reverse transcriptase inhibitor,
PI protease inhibitor, BE Belgium, GR Greece, NL the Netherlands, SL Slovenia, HSX heterosexual, MSM Men having sex with men? unknown route of transmission.
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to HXB2 (range: 4–9) and median of 5 when compared to
consensus B (range: 3–8).
In vivo evolution of transmitted drug resistant HIV-1
variants
The vast majority (51/55) of TDRM persisted during the
first year of follow-up. For 24/31 patients a third and
sometimes a fourth genotypic analysis was performed at
a median of 28 months (range: 14–99 months) after the
first sample. During this more extensive follow-up period
of up to eight years, all resistance mutations present at
one year after diagnosis persisted in the plasma (Table 1).
To gain more understanding of in vivo persistence of
TDRM, we performed a comprehensive analysis of in vivo
viral evolution during the follow-up. Viruses harboring
protease drug-resistance mutations selected a median of 1
(range: 0–1) additional polymorphisms in protease during
the first year of follow-up. Likewise, viruses harboring
drug-resistance mutations in RT selected a median of 1
(range 0–3) additional RT polymorphisms (Table 2).
As a measure of evolution at the nucleotide level, the
p-distance between baseline and follow-up sequences
was calculated. For the majority of patients, this re-
vealed a very low p-distance between baseline and one
year, confirming limited viral evolution. In line with this
observation, the dN/dS ratio of the viral populations,which is an indicator of selection, did not change signifi-
cantly in any patient (Table 2). However, in all transmitted
viruses at least one change at a polymorphic site was ob-
served, which is described in Table 2.
Impact of frequently observed TDRMs on in vitro RC
We determined the impact of TDRM on viral RC by intro-
ducing frequently observed drug-resistance mutations
M46I, M46L or L90M in protease or M41L, M41L +
T215Y or K103N in RT in the background of the lab
strain HXB2 by site-directed mutagenesis (Figure 1).
Viruses were named according to mutations and origin;
the prefix “SDM” indicates site-directed mutagenesis. The
RC of all viral variants was determined in primary periph-
eral blood mononuclear cells (PBMCs), which are natural
target cells for HIV. Site-directed mutants HIV-M184V, −I
and –T with a known impact on RC were used as con-
trols, and to enable comparison of RC between various
experiments [27]. The difference in RC between HIV-
WT, −M184V and -M184I has been demonstrated to
be biologically relevant in vivo [28,29].
All mutations caused a decrease in RC as compared to
HIV-WT, except for mutation L90M in protease. The re-
duction in RC of the M41L, M41L + T215Y and K103N
variants was comparable to each other, and to controls
HIV-M184V and -I. M46I and M46L in protease resulted
in the most severe reduction of RC (Figure 1).
Table 2 Evolution of transmitted drug resistant HIV variants
ID Months
after
first
sample
Protease amino acid 4-99 Reverse transcriptase amino acid 41-230
Baseline Reversion Additional mutations Baseline Reversion Additional
mutations
Transmitted variants harboring only NRTI-related mutations
P01 0 S37N L63P I93L M41L V60I I135T S162C
K166R R211G L214F
10 -K166R +V106IV
16 V106IV > I
P02 0 T12A K14KR
Q18HQ L19IL
S37N L63P I93L
M41L V60I I135T
S162G K166EK I167F
R211G L214F
12 -K14KR,
−Q18HQ
L19IL > IKLQ -S162G -I167F K166EK > KR
28 T12A > AT L19IKLQ > IL R211G > GR +T165IT
P03 0 T12A I13V L19I
S37NS I64V C67CR
M41L V60I F61FS
E122K D123E I178L
V179IV E203EG
Q207EQ L214F
11 -S37NS -I64V
> IV -C67CR
+I62IV -F61FS -E203EG +S162X V179IV > I
Q207EQ > KQ +
R211KR
32 T12A > AT I62IV > V -S162X -I178L -V179I Q207KQ > EQ
P04 0 E35D S37D D60E
I62V L63P A71T
I72V I93L
K49R V60I V118I
E122K D123DE I135R
S162D L210LS R211G
11 +I72V > EV -L210LS D123DE > E
S162D > S162X +
T200IT + E204EK
25 +T12AT + K14KR + V77IV -S162X, R211G > GR
-E204EK
+T165IT
P05 0 S37N I64V K64R R83K I178L
I202V L214F T215D
12 +M36I -K64R +S68N + E122K
99 +I13IV + K14KR + K45KR R83K > KR, −I202V +A158AS + S162T
P06 0 L10I K14EV S37N
L63T E65EV I72T
V77I I93L
E122K I142V D177E
Q207E L214F T215S
14 K14EV > E E65EV > V -E122K > EK
21
P07 0 I15L L19V S37N
R41K D60E L63P
I72IV I93L
V60I S68G R83K V90I
A98S E122P D123DEG
I135L S162C D177E
I202IV R211K L214F
T215D
11 +M36IM −202IV D123DEG > DE
27 -M36IM L19V > IV D123DE > DEG +
T200IT
P08 0 L10I S37N R41K
I62V L63S V77I
I93L
V60I S68G E122K
I135V S162NS T165IT
Q174HQ G196E
R211G L214F T215IT
13 -S162NS -T165IT-
T215IT
Q174HQ > H
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Table 2 Evolution of transmitted drug resistant HIV variants (Continued)
P09 0 S37N I62V L63T
I64L V77I
S68T E122K I135V
T139A G196E Q197R
L214F T215AT
13 -T139A +H198HR
20 +R57KR -H198HR S68T > AT +
T139AT +
T215AT > A
P10 0 I15V E35D S37D
D60E L63P V77I
I93L
S68K T69N A98S
L100LV E122K D123E
I135R N136NT Q145E
S162C I178M E194D
I195L G196E T200A
I202V Q207K R211G
L214F K219N H221Y
K223Q
11 +R41K -L100LV -N136NT
44 +K45KR + R57KR -I135R +K49KR
P11 0 S37H R41KR R57K
Q61D
V60I D67N T69E
V106I D121Y I135T
S162C D177E G196E
E203D Q207E R211KR
L214F T215C
13 -V106I L214F > FL +T200IT
P12 0 L10I T12S L19I
L63T
V60I D67G S68G
I135T I178M R211KR
L214F T215C K219E
11 -L10I L19I > T -R211KR +E122EK
24 +L10I L19T > I + I62IV -E122EK -I135T +Q207LQR +
R211KR
P13 0 T12S L19I L63T
I64IM
V60I D67G S68G
A158S I178M L214F
T215C K219E
12 I64IM >M +E40Q
14 -E40Q
P14 0 T12S L19T L63T V60I D67G S68G
I135IT I178M L214F
T215C K219E
14 +E122EK I135IT > T
P15 0 L19I E35D S37N
R57KR L63P V77IV
I93L
M41LT69S D86DE
E122K S162C I178L
E204DE Q207EKQ
L210E R211K L214F
T215ST
11 -R57KR V77IV > I Q207EKQ > KQR
L210E > DE
39 V77I > IV S37N > DN + R57KR +V60VI + I195IL
Q207KQR > x
L210DE > E
R211K > KN
77 ’-R57KR S162C > CS E204DE >
DEKNR211KN > K
P16 0 L19I E35D S37NS
L63P V77IV I93L
M41L T69S D86E
K104KR E122K S162C
I178L E204DE
Q207KQR L210E
R211DEKN
L214FT215S
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Table 2 Evolution of transmitted drug resistant HIV variants (Continued)
13 I72IM -K104KR T69S > AS
S162C > CW
33 -I72IM E35D > DEKN S37NS > N V77IV
> I
-E204DE T69AS > S
S162CW >W+
E194DE Q207KQR
> R R211DEKN > D
49 E35DEKN > DE -E194DE Q207R > QR
R211D > DEKN
P17 1 E35D R41K L63P
I93L
K103N E122K D123E
R211K L214F
12 +K173KT +
D177DN
30 +S37N -K173KT +Q174HQ +
Q207QR R211K >
KQ
Transmitted variants harboring only NNRTI-related mutations
P18 0 L10IV I13IV I15IV
L19IL I62V L63PS
I64LV C67S V77I
K64R K103N E122K
D123E K173EK
Q174QR V179I T200A
R211K L214F
12 -L19IL L10IV > I L63PS > X I64LV > V -K173EK -Q174QR +D177DN
28 +R72RS + Q174QR
P19 0 L10I I15V S37T
R41K C67G G68E
H69R
V60I K103Q E122K
D123E I142V R211K
L214F
10
12
59 G68E > D + T200IT
P20 0 T12N K14R S37N
R41KR I64V
E122K D123E I135T
Y181C T200A I202V
R211K L214F
11 S37N > NS
49 K14R > KR
-R41KR
+E35D S37NS > N + L63HQ E122K > EK I135T >
IT
D123E > AE
P21 0 I13V S37NT L63P
A71AG
I50N G51W P52A
V60IV R83K A98AG
K101H S105LS D177E
V179I G190A R211K
L214F
10 -A71AG S37NT > NST -I50N -G51Q -P52A
-A98AG -S105LS
V60IV > I + E122K
K173EK
P22 0 I13V M36T S37N
L63P
S48Q R83KR K101H
D123DE D177E V179I
G190A L214F H235R
13 M36T > IMT -S48Q -H235R D123DE > DEKN +
S162CS
P23 0 S37N M46L D60E
I62V L63S I72V
V77I I93L
K49R V60I V118I
I135R E169D R211G
L214F
14 +F87FL + E204EK
22 V60I > IV -F87FL-
E204EK
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Table 2 Evolution of transmitted drug resistant HIV variants (Continued)
P24 0 E35DE S37N M46L
D60E I62V L63S I93L
K49KR V60I V118I
E122K I135R R211G
10 -E35DE -I93L +K70KR -K49KR
29 -K70KR +K104KR + S162C
P25 0 E35D S37NM46L
D60E I62V L63S
I93L
K49R V60I V118I
E122K I135R R211G
14 +R41KR +D123E
23 L63S > PS I93L > IL D123E > DEKN +
I178ILV
Transmitted variants harboring only PI-related mutations
P26 0 E35D S37N M46L
D60E I62V L63S
I93L
K49R V60I V118I
E122K D123DN I135R
R211G
14 +L19IL -D123DN +T165IT
26 L19IL > X + A71AV T165IT > I +
E204EK
P27 0 E35D S37N M46L
D60E I62V L63S
I93L
K49R V60I V118I
E122K I135R N136NT
S162NS I167IT R211G
13 L63S > APS -N136NT -S162NS
-I167IT
38 -E35D L63APS > A
P28 0 L19T S37N L63P
L90M I93L
E122KT200A L214F
K220X
13 S37N > NS -K220X
Transmitted variants harboring mutations against two drug classes
P29 0 T4IT T12S L19IV
L63X
V60I D67G S68G
K70KR I178M
Y181CY L214F
T215C K219E
10 -T4IT +L10I L19IV > I L63X > T -K70KR -Y181CY +I135IT + E204EG
+ R211KR
46 -L10I T12S > PS + G16AG L19I > IV +
M36IM L63T > PT + I64IV
-E204EG -R211KR I135IT > T
P30 0 L10I I13V I15V I62V
L63P G73S L90M
V60I A98S K103N
D121Y D123E I135T
R172KR L214F
12 -G73S I135T > IT -R172KR
18 +S37NS +K102KR
P31 0 L10I I15V K20R
E35D M36I S37N
I54V Q58E L63P
A71V V82A L90M
M41L K43N V60I
D67N E122P I135T
E138A I142V L210W
R211M L214F T215D
10 +F53FL -L214F +T139I + I178IV
Patient-derived sequences are compared to HXB2. Bold positions indicate positions related to drug resistance, italics indicate polymorphisms of HXB2 compared
to consensus B.
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frequently observed TDRM
Subsequently, the RC of frequently observed TDRM was
determined in their natural genetic background (Figure 1).
We constructed recombinant viruses using patient-
derived protease containing M46L, M46I or L90M, orpatient-derived n-terminus of RT containing M41L or
K103N into HXB2. In addition, two more complex trans-
mitted viruses were studied: a protease-variant containing
I54V + V82A+ L90M and an RT-variant carrying M41L +
T69S + L210E + T215S. Patient-derived clones are indi-
cated by the prefix “p”, followed by the TDRM.
Gng
 p
24
/m
l
Days post infection
DA
EB
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Figure 1 (See legend on next page.)
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Figure 1 Impact of frequently observed transmitted drug-resistance mutations on viral replicative capacity. The replicative capacity of
site-directed mutant (SDM) viruses and patient-derived viruses was determined by infecting donor peripheral blood mononuclear cells with equal
amounts of viral p24. In all experiments, control viruses HIV-M184V, −M184I and –M184T and wild type (WT) HIV were used as reference viruses.
Representative experiments are shown in A-C and D-F. Error bars indicate standard deviation (SD) of mean within one experiment. Four biological
replicates were performed for all viruses. (A-C) Replicative capacity of SDM-viruses (B, C) compared to control viruses (A). (D-F) Replicative
capacity of patient-derived viruses (E, F) compared to control viruses (D). RC of WT and control viruses (A, D) is indicated in the corresponding
graphs by a square, and the range in RC of WT and M184T by the grey area. (G) The median p24 production of both experiments as a percentage
of WT in the corresponding experiment for all protease or reverse transcriptase mutant viruses. Error bars indicate range (n = 4).
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M184I and –V, indicating a diminished replication. The
RT variant pK103N had an RC comparable to HIV-WT
and the RC of pL90M was higher than HIV-WT. For
M41L, it has been described that V60I and S162A func-
tion as compensatory mutations in transmitted HIV-1
variants [30]. We selected a patient-virus with M41L but
without the potential compensatory mutations (pM41L).
In this genetic background, the viral RC was as low as
HIV-M184T and even lower than SDM-M41L. However,
in vivo the variant containing this M41L mutation per-
sisted for 8 months without selection of V60I or S162A
before the patient initiated therapy (data not shown).
Interestingly, except for the pM41L variant, all patient-
derived viruses had a higher RC than the corresponding
site-directed mutants (Figure 1). The RC of all protease
mutation-harboring patient-derived viruses was higher
than the corresponding SDM-viruses, and the RC of
pL90M and pI54V + V82A + L90M were even higher
than WT. In line with these results, the RC of pK103N
and pM41L + T69S + L210E + T215S surpassed the RC
of the corresponding SDM-viruses to the level of wild
type virus. These observations suggest the presence of
compensatory mutations in the genetic backbone of
patient-derived viruses at the moment of diagnosis that
are able to restore viral RC.
Discussion
In this study we strived to explain the in vivo persistence
of the majority of TDRM in patients diagnosed with a
drug-resistant HIV-1 variant. We selected patients diag-
nosed with HIV-1 containing limited profiles of TDRM,
which are the most frequently transmitted variants as
shown by large epidemiological studies [2,4]. In our pa-
tients, the vast majority of TDRM persisted for at least a
year and up to eight years, confirming observations from
previous studies that except for M184V/I, TDRM gener-
ally persist for longer than one year [10,13-25].
To explore the potential role of viral RC in persistence
of TDRM, we investigated the impact of TDRM on the
RC. In vitro determination of RC in PBMCs demon-
strated that most site-directed mutant viruses harboring
1–2 frequently observed TDRMs had a reduced RC.
However, in line with in vivo persistence the majority ofpatient-derived viruses had a higher RC than the corre-
sponding SDM viruses. This suggests that polymorphisms,
which may be present at baseline, can act as compensatory
mutations. Our extensive sequence analysis demonstrated
limited evolution on polymorphic positions, suggesting
that in many transmitted HIV variants harboring TDRM
compensatory mutations are already present at diagnosis.
Of the investigated site-directed mutant viruses, T215Y
is known to evolve to atypical or partial revertant amino
acids. Such alternative amino acids are known to confer
limited impact on viral RC [9,18,31], which is in line with
the observed persistence of revertant and atypical T215
variants in our and other studies [10,13,15-25].
Interestingly, when present as a SDM in the commonly
used lab strain HXB2, K103N decreased the RC in our ex-
periments although this NNRTI-related mutation has
been described to have a low impact in several [32-34] but
not all [35] previous studies. This discrepancy may be due
to the use of different assays or differences in replication
caused by polymorphisms in lab strains. Indeed, the RC of
patient-derived K103N was similar to WT virus, indicating
that polymorphisms can restore viral RC. This may ex-
plain the in vivo persistence of K103N in our and previous
studies [10,21].
Several papers have described the impact of some drug
resistance mutations on the RC of HIV-1 [16,32,33,35].
To our knowledge, the viral RC of frequently observed
protease and RT TDRM has never been compared. Our
data reveal that site-directed mutations at position 46 in
protease have the most severe impact on RC.
Lack of reversion of the TDRM could be explained by
a relatively small viral population size resulting in lim-
ited evolution. However, the median plasma HIV-RNA
level of the included patients is similar to the HIV-RNA
generally observed for newly diagnosed patients in the
SPREAD programme [3]. Furthermore, although viral evo-
lution was limited, in all transmitted viral variants changes
at polymorphic sites were observed, indicating that repli-
cation could result in molecular evolution.
Certain resistance mutations such as M46I in protease
have been described to decrease recognition of epitopes
by certain HLA types [36]. As a result, also the immune
system may affect viral evolution and persistence of TDRM.
However, the majority of frequently observed TDRM may
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[36,37] and as such, it is unlikely that the immune system
is the major driving force behind persistence of all TDRM.
We previously hypothesized based on an extensive lit-
erature study that the lack of reversion is related to the
RC of transmitted HIV-1 variants harboring TDRM [9].
The currently described data confirms that TDRM may
persist due to a high RC of the transmitted HIV-1 vari-
ant. Alternatively, the selection of additional mutations
may restore the RC or result in compensatory fixation
[30,38]. This important role of polymorphisms was sup-
ported by the differential impact of TDRM in the pres-
ence of patient-derived genetic background compared to
site-directed mutants. For all but one investigated fre-
quently observed TDRM, in vitro RC of patient-derived
virus was higher than the corresponding SDM. A strik-
ing example is M46L. Although the single presence of
M46L in HXB2 causes a large decrease in viral RC, this
defect in RC is largely restored when M46L is present in
a patient-derived genetic background.
M41L is one of the most frequently observed TDRM,
and is an intriguing example emphasizing the impact of
the genetic background on RC. As a single mutation, M41L
in the background of wild type virus HXB2 decreased the
RC. This decrease was even more pronounced in the gen-
etic background of pM41L, which was specifically selected
for this study because of the absence of known compensa-
tory mutations V60I and S162A [30]. In sharp contrast,
pM41L + T69S + L210E + T215S, the patient-derived virus
with an extensive profile containing a M41L in the pres-
ence of the compensatory mutation V60I had a similar RC
as wild type virus [30].
In addition, compensatory mutations may be observed
outside the target gene of the antiviral compound. It has
been demonstrated that mutations in gag may help to
compensate the reduced protease activity conferred by
resistance mutations in the protease itself [39]. Unfortu-
nately sequencing of gag is usually not included in rou-
tine genotyping within Europe, impeding investigation of
a potentially compensatory role of gag in this study. For
RT, compensatory mutations may also be present in the
connection domain [40], which again is not included in
routine genoptyping.
For only a subset of patients we had laboratory evidence
of recent infection. We cannot exclude that patients were
initially infected with a viral variant harboring a more ex-
tensive resistance profile and that some of these mutations
had reverted before the patients were diagnosed. As such,
the observed limited evolution of pol may be a result of
viral adaptation before diagnosis or may even have taken
place in previous hosts. By using a more sensitive se-
quence method, we might have been able to increase the
detection of TDRM in the included patients [11]. How-
ever, we have previously used ultra-deep sequencing toinvestigate the quasispecies in plasma of patients who
were newly diagnosed with an HIV-1 variant harboring a
single NRTI-related resistance mutation. In most patients
we were unable to detect viral minority variants harboring
more extensive resistance profiles in the plasma, which
may be suggestive of infection with a circulating HIV-1
variant harboring a limited resistance profile [41]. It is not
unlikely that onward transmission of highly stable HIV-1
variants harboring limited resistance profiles greatly con-
tributes to the current epidemic of transmitted drug re-
sistant HIV-1 variants. Indeed, phylogenetic studies have
demonstrated that onward transmission by untreated pa-
tients is a major source of transmission of drug-resistant
HIV-1 [42-44].
It is of great clinical importance to be able to distin-
guish whether transmitted drug resistant HIV-1 variants
harbor complex but partially reverted resistance profiles
or circulating HIV-1 variants containing limited resistance
profiles. For the frequently observed NNRTI-resistance mu-
tation K103N, it is well-known that it causes high levels of
resistance against all first generation NNRTIs [45,46]. Even
when K103N is present as minority variant, it can contrib-
ute to therapy failure [11]. Fortunately, the recently ap-
proved second-generation NNRTIs remain active against
HIV-1 harboring a single K103N [47,48]. In contrast, we
have demonstrated that the NRTI-related M41L in RT has
limited impact on selection of resistance against currently
used NRTIs [49]. M46I/L or L90M as a single TDRM in
protease may cause low level resistance to commonly used
protease inhibitors such as lopinavir.
Conclusion
In conclusion, we confirmed persistence of the most fre-
quently observed TDRM. All transmitted HIV-1 variants
harbored additional polymorphisms, with limited selection
of additional mutations. Limited reversion of TDRM is in
concordance with the high in vitro RC of patient-derived
viruses harboring TDRM. As SDM viruses with the same
TDRM as patient-derived viruses have a lower RC in vitro,
we propose that polymorphisms that function as compen-
satory mutations (partially) restoring viral RC explain the
in vivo persistence of TDRM. The stability of transmitted
drug resistant HIV-1 variants can facilitate onward trans-
mission of these viruses.
Methods
In vivo evolution
Ethics statement
Ethical requirements differ between countries according
to national legislation. In countries where a national sur-
veillance system was established, legally no informed con-
sent was needed. In other countries, approval was obtained
by the institutional medical ethical review committees. All
data were anonymized at national level.
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Patients from four countries participating in the SPREAD-
programme (Belgium, Greece, the Netherlands, Slovenia)
were included. For all included patients, a baseline geno-
typic resistance test performed on a plasma sample within
three months after diagnosis of HIV-1 infection revealed
at least one mutation on a position associated with trans-
mitted drug resistance as described in the mutation list as
recommended by the WHO [26]. Patients were included
on the basis of sample availability; a base line sample and
a sample one year (10–14 months) later. If available, a
sample at later time points were included. All included
patients were at least 18 years of age and not exposed to
antiretroviral therapy during the study period.Sequence analysis
Genotypic resistance tests were performed by population
sequencing of the viral protease and part of reverse tran-
scriptase using commercially available assays or in-house
methods covering at least amino acids 4–99 of protease
and amino acids 30–249 of RT. All laboratories collabo-
rated in the quality control program of ESAR to ensure
high quality genotypic data [3,4]. HIV-1 subtype was de-
termined using REGA 2.0 [50]. To investigate evolution,
the p-distance and the ratio of the proportions of syn-
onymous and nonsynonymous substitutions (dS/dN ratio)
were calculated using MEGA 5.05. The p-distance is the
proportion of nucleotides between two sequences that has
been changed. The dS/dN ratio, a measure of selection
pressure [51], was calculated with the Nei-Gojobori method
and statistically tested with a Z-test.In vitro determination of replicative capacity
Virus panel
Mutations M46I, M46L and L90M in protease and M41L,
M41L + T215Y and K103N in RT were introduced in
HXB2 by site-directed mutagenesis using the previously
described vector systems CP-MUT and NRT-MUT [52]
and the following primers: M46I 5′-GGA AAC CAA
AAA TAA TAG GG-3′ (HXB2 nucleotides 2380–2396),
M46L 5′-GGA AAC CAA AAC TGATAG GG-3′ (HXB2
nucleotides 2380–2396), L90M 5′-GAA ATC TGA TGA
CTC AGA TTG-3′ (HXB2 nucleotides 2511–2532),
M41L 5′-ATT TGT ACA GAG CTG GAA AAG GAA
G-3′ (HXB2 nucleotides 2658–2682), K103N 5′-GTT
ACT GAT TTG TTC TTT TTT AAC CC-3′ (HXB2 nu-
cleotides 2844–2869), T215Y 5′-TGTCTG GTG TGTAAA
GTCCCCACC-3′ (HXB2 nucleotides 3181–3204).
Baseline patient-derived viral protease genes harboring
M46I, M46L, L90M or I54V + V82A + L90M or the N-
terminus of RT containing M41L, M41L + T69S +
L210E + T215S or K103N were introduced into HXB2
using the same vector system [52].Clones were obtained and sequence analysis was per-
formed to verify resemblance to population sequences.
Subsequently, at least three recombinant virus stocks
were generated by Lipofectamine 2000 (Invitrogen) trans-
fection of HEK293T cells according to manufacturer’s
guidelines. TCID50 was determined by end-point dilu-
tion in MT2 cells, demonstrating similar replication in
this T cell line in all cases. A random clone was selected
and quantified by p24 ELISA (Aalto Bioreagent, Dublin,
Ireland) for the RC analysis.
RC analysis
PBMCs were isolated from HIV-seronegative blood donors
by Ficoll-Paque density gradient centrifugation and stored
in liquid nitrogen until use. To minimize differences be-
tween batches caused by variation between donors, each
batch of PBMCs consisted of five combined donors. The
RC of the virus panel was determined by infecting 5×106
phytohaemagglutinin-stimulated (2 mg/L) donor PBMCs
with the equivalent of 40 ng HIV-1 p24 for two hours.
Subsequently, cells were washed twice and maintained for
14 days in RPMI1640 with L-glutamine (BioWhittaker),
10% fetal bovine serum (Biochrom AG), 10 mg/L gentami-
cin (Gibco) and 5 U/ml IL-2. Cell-free supernatant was
harvested daily for monitoring of the p24 production. The
RC of either the SDM-viruses or the patient-derived vi-
ruses was compared to the RC of control viruses (WT,
HIV-M184V, −M184I and –M184T). By comparing vi-
ruses containing only the mutation(s) or gene of interest
in the exact same HIV-WT background, it is possible to
determine the impact of these relevant mutation(s) or
genes on viral RC. For all viruses, replication curves were
performed in four biological replicates divided over two in-
dependent experiments. The mean p24 production of two
replicates within representative experiments are indicated
in Figure 1A-C for protease and 1D-F for RT. Figure 1G
represents the median p24 production relative to HIV-WT
of all four replicates on day 7 post infection.
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